Agreements (Tables)

9 Months Ended

Sep. 30, 2023

Schedule Of Total Purchase Price Was Allocated To The Acquired Assets Based On Their Relative Fair Values


License and acquired intangibles	$	33,569
Acquired research and development inventory expensed from asset acquisition		4,130

Total purchase price	$	37,699

Summary of Aggregate Amount Paid for the Assets Acquired

The following table summarizes the aggregate amount paid for the assets acquired by the Company in connection with the acquisition of FYCOMPA

(in thousands):


Base cash payment	$	160,000
Cash paid for pro-rated prepaid expenses		1,576
Reimbursement on base purchase price (i)		(3,238	)
Transaction costs (ii)		5,870

Total purchase consideration	$	164,208

(i)

Recorded in prepaid expenses and other current assets in the accompanying consolidated balance sheet as of the acquisition date and reimbursement was fully applied as of June 30, 2023

(ii)

As of September 30, 2023 the full $5.9 million has been paid in cash

Summary of Total Purchase Price Allocated to Acquired Assets

The total purchase price was allocated to the acquired assets based on their relative fair values, as follows (in thousands):


Inventory	$	4,100
Prepaid expenses and other current assets (samples)		130
Prepaid commercialization expenses		1,576
Property and equipment, net		433
License and acquired intangibles for FYCOMPA ®		158,143
Accrued preclinical and clinical trial expenses		(174	)

Total purchase consideration	$	164,208

Vamorolone [Member]

Asset Acquisition [Line Items]

Summary of Aggregate Amount Paid for the Assets Acquired

The following table summarizes the aggregate amount paid for the assets acquired by the Company in connection with the acquisition of vamorolone and the strategic equity investment (in thousands):




Initial cash payment	$	75,000
Investment in Santhera		13,465
Transaction costs		6,513

Total purchase consideration	$	94,978

Summary of Total Purchase Price Allocated to Acquired Assets

The total purchase price was allocated to the acquired assets based on their relative fair values, as follows (in thousands):


License and acquired intangibles for vamorolone (IPR&D)	$	81,513
Investment in Santhera (i)		13,465

Total purchase consideration	$	94,978

(i)

The fair value of the investment in Santhera was determined based on the closing market price (CHF 8.25) of Santhera shares and the exchange rate (1.1537) of CHF to USD on the date the shares were transferred, July 19, 2023.